Cyclic changes in the uterine tissue content of F-prostaglandins and the role of prostaglandins in ovulation in mice

Mapping PTGERs to the Ovulatory Follicle: Regional Responses to the Ovulatory PGE2 Signal

Prostaglandin E2 (PGE2) is a key intrafollicular mediator of ovulation in many, if not all, mammalian species. PGE2 acts at follicular cells via four distinct PGE2 receptors (PTGERs). Within the ovulatory follicle, each cell type (e.g., oocyte, cumulus granulosa cell, mural granulosa cell, theca cell, endothelial cell) expresses a different subset of the four PTGERs. Expression of a subset of PTGERs has consequences for the generation of intracellular signals and ultimately the unique functions of follicular cells that respond to PGE2. Just as the ovulatory LH surge regulates PGE2 synthesis, the LH surge also regulates expression of the four PTGERs. The pattern of expression of the four PTGERs among follicular cells before and after the LH surge forms a spatial and temporal map of PGE2 responses. Differential PTGER expression, coupled with activation of cell-specific intracellular signals, may explain how a single paracrine mediator can have pleotropic actions within the ovulatory follicle. Understanding the role of each PTGER in ovulation may point to previously unappreciated opportunities to both promote and prevent fertility.

Effects of indomethacin on preovulatory follicles in immature, superovulated mice

In order to demonstrate the possible role of prostaglandins in preovulatory follicular development, immature mice superovulated with pregnant mare serum followed 40 hours later by luteinizing hormone (LH) were treated with the prostaglandin-synthetase inhibitor, indomethacin. Indomethacin (10 mg/kg) injected at varying intervals prior to or following LH inhibited ovulation most effectively when administered within 2 hours of the ovulatory gonadotropin. This inhibition was accompanied by (1) suppression of the morphological changes normally occurring within the follicular wall during preovulatory development and (2) failure of germinal vesicle breakdown (GVBD) in two-thirds of the follicles examined. When GVBD occurred, indomethacin treatment appeared to delay meiotic maturation. Cumulus tissue was more compact than in control follicles and maintained a close association with the oocyte. These results suggest that alterations in the morphology of the follicle prior to ovulation--specifically, thinning of the apical follicular wall and meiotic maturation--are regulated by prostaglandins.

An intrauterine silastic system for the sustained release of indomethacin

Rats with unilateral intrauterine silastic devices (made from 60 to 100 mg indomethacin/3 g silastic mixture) were found to have regular estrous cycles. No interference with body weight gain occurred in animals with the 100 mg/mix devices. The patterns of indomethacin release were dependent on the initial loading of the drug in the device, with the 60 and 100 mg/mix devices having delivery periods of approximately 50 days and 120 days respectively. Nevertheless, the absolute quantities of indomethacin delivered at any chosen time was remarkably similar for the two different loadings, suggesting that the properties of the external environment govern the total amount of drug released at specific times from these systems in utero.

Inhibition of superovulation and alteration of ova transportation in hamsters by prostaglandin and DL-204-IT, an anti-fertility agent

The compound 2(3-ethoxyphenyl)-5, 6-dihydro-s-triazole- [5, 1-2] isoquinoline (DL-204-IT or L-11204) inhibited PMS-induced superovulation and reduced the number of recoverable ova in the oviducts of hamsters. PGE2 non-significantly reduced the number of ova shed but significantly decreased the number of oviductal ova. DL-204-IT was more potent than PGE2 for these effects. Administration of both compounds resulted in a complete block of ovulation. Inhibition of prostaglandin metabolism by DL-204-IT may be the cause for these effects, but no direct evidence is presently available.

Inhibition of ovulation and fertilization by indomethacin and effect of prostaglandin-F2 alpha on early pregnancy in the rabbit

Ovulation induced by HCG in rabbits was blocked by a single subcutaneous injection of 6 mg/kg indomethacin given 6 h after the insemination and HCG treatment. In addition, a time-dependent inhibition in the fertilization rate after indomethacin treatment was also recorded. This suggests that indomethacin, when given at a critical time and at an appropriate dose level, not only blocks ovulation but also interferes with fertilization. Treatment with graded amounts of prostaglandin-F2 alpha incorporated in a Silastic-polyvinylpyrrolidone-gel (PVP) had marginal to no effect after intravaginal placement on 4- or 6-day pregnancy. However, 5 mg PGF 2 alpha/ Silastic-PVP tube when placed intravaginally on Day-7 of pregnancy resulted in termination of pregnancy in 66% of the treated does. This implies that young corpora lutea are resistant of PGF2 alpha treatment and that pregnancy at the time of ovo-implantation can be terminated by PGF2 alpha incorporated in a Silastic-PVP tube.

Effects of prostaglandin E2 and DL204 IT, an inhibitor of prostaglandin degradation, on ovulation and ovum transport in the hamster

The effects of 2(3-ethoxyphenyl)-5,6-dihydro-s-triazole-[5,1-a]isoquinoline (L-11204 or DL 204 IT and PGE2 on ovulation and ova transport were studied. DI 204 IT was administered in doses of 0.2-25 mg/kg s.c. on the day of estrus. A smal reduction in ovulating follicles was observed 96 hours later, but only at the 5 mg/kg dose level. At all dose levels, however, DL 204 IT caused a dose-related reduction in the number of ova in the oviducts. PGE2 at a total dose of 2 mg/animal s.c., administered in 4 divided doses over the second and third day of the cycle did not affect ovulation or ova transport. PGE2 plus DL 204 IT (5 mg/kg), however, completely blocked ovulation in all but one animal. That animal had one ovulated follicle and a single ova was recovered from its oviduct.

Prostaglandin F2alpha: modification of its abortifacient effect by depo-estradiol cypionate in rats

Insertion of a Silastic-PVP implant containing 150 mug PGF2alpha into one of the uterine horns or administration of a single subcutaneous injection of 4 mug of Depo-Estradiol Cypionate (ECP) did not induce abortion in pregnant rats. However, a combined treatment with 150 mug of PGF2alpha in a Silastic-PVP implant and 4 mug of ECP induced abortion in all treated rats. Apparently, ECP stimulated endogenous production of PGF and consequently enhanced the effect of the administered 150 mug of PGF2alpha. The release of 3H-PGF2alpha from Silastic-PVP implants was faster after intrauterine or intraperitoneal than after subcutaneous insertion. The release rate of 3H-PGF2alpha from Silastic-PVP implants in vitro was comparable to that observed after subcutaneous placement of similar implants. It is suggested that administration of estrogen combined with PGF2alpha might shorten the interval between treatment with PGF2alpha and abortion. Moreover, a Silastic-PVP implant would lend itself as a better method of administration, releasing PGF2alpha locally, slowly, and continuously.